Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Profectus BioSciences Snags $3.5M from NIH for HIV Vaccines

By Drug Discovery Trends Editor | July 30, 2014

Profectus BioSciences Inc., a clinical-stage vaccine platform company developing novel PBS Vax vaccines for the treatment and prevention of infectious diseases, announced the award of two Small Business Innovative Research (SBIR) grants totaling $3.5 million from the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).
 
Profectus will use the awards to support the optimization and testing of a novel DNA therapeutic vaccine strategy against simian immunodeficiency (SIV) infection of macaques, the prevailing animal model for human immunodeficiency virus (HIV), in collaboration with Dr. Deborah Fuller, Associate Professor in Microbiology at the University of Washington and Washington National Primate Research Center.
 
The effort exploits a key observation published by Dr. Fuller that a skin-delivered therapeutic DNA vaccine co-formulated with a novel adjuvant-stimulated mucosal T cell response in SIV-infected macaques led to durable viral suppression in these animals after ceasing standard antiretroviral therapy.
 
As a component of the National Institutes of Health’s HIV “Cure Agenda,” this collaboration aims to improve this outcome by using more potent adjuvants from Profectus’s portfolio and a novel DNA delivery device that more efficiently delivers DNA into the skin.     
 
Date: July 29, 2014
Source: Profectus BioSciences

Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE